A
Aibing Xu
Publications - 12
Citations - 619
Aibing Xu is an academic researcher. The author has contributed to research in topics: Hepatocellular carcinoma & Internal medicine. The author has an hindex of 5, co-authored 5 publications receiving 67 citations.
Papers
More filters
Journal ArticleDOI
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
Zhenggang Ren,Jianming Xu,Yuxian Bai,Aibing Xu,Shundong Cang,Chengyou Du,Qiu Li,Yinying Lu,Yajin Chen,Yabing Guo,Zhendong Chen,Baorui Liu,Weidong Jia,Jian Wu,Junye Wang,Guoliang Shao,Bixiang Zhang,Yunfeng Shan,Zhiqiang Meng,Jianbing Wu,Shanzhi Gu,Wei Yang,Chao Liu,Xuetao Shi,Zhenyuan Gao,Tao Yin,Jiuwei Cui,Ming Huang,Baocai Xing,Yilei Mao,Gao-Jun Teng,Yanru Qin,Jinhai Wang,Feng Xia,Guowen Yin,Yong Yang,Mingxia Chen,Yan Wang,Hui Zhou,Jia Fan +39 more
TL;DR: The phase 2-3 ORIENT-32 study as discussed by the authors compared sintilimab (a PD-1 inhibitor) plus IBI305, a bevacizumab biosimilar, versus sorafenib as a first-line treatment for unresectable HBV-associated hepatocellular carcinoma.
Journal ArticleDOI
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial.
Shukui Qin,Feng Bi,Shanzhi Gu,Yuxian Bai,Zhendong Chen,Zishu Wang,Jieer Ying,Yinying Lu,Zhiqiang Meng,Hongming Pan,Ping Yang,Helong Zhang,Xi Chen,Aibing Xu,Chengxu Cui,Bo Zhu,Jian Wu,Xiaoli Xin,Jufeng Wang,Jinlu Shan,Junhui Chen,Zhendong Zheng,Li Xu,Xiaoyu Wen,Zhenyu You,Zhenggang Ren,Xiufeng Liu,Meng Qiu,Liqing Wu,Feng Chen +29 more
TL;DR: In this article, a multikinase inhibitor and a deuterated sorafenib derivative were compared in phase Ia and Ib hepatocellular carcinoma (HCC) studies.
Journal ArticleDOI
Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Shukui Qin,Qiu Li,Shanzhi Gu,Xiaoming Chen,Lizhu Lin,Zishu Wang,Aibing Xu,Xi Chen,Cuncai Zhou,Zhenggang Ren,Lin Yang,Li Xu,Yuxian Bai,Lei Chen,Jun Li,Hongming Pan,Bangwei Cao,Weijia Fang,Wei Wu,Ge Wang,Ying Cheng,Zhuang Yu,Xu Zhu,Da Jiang,Yinying Lu,Huaming Wang,Jianming Xu,Li Bai,Yunpeng Liu,Hailan Lin,Changping Wu,Yang Zhang,Ping Yan,Chunlei Jin,Jianjun Zou +34 more
TL;DR: The AHELP trial as discussed by the authors evaluated the efficacy and safety of apatinib in patients with pretreated advanced hepatocellular carcinoma, and showed that the drug significantly improved overall survival compared with placebo, with a manageable safety profile.
Journal ArticleDOI
Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.
Feng Bi,Shukui Qin,Shanzhi Gu,Yuxian Bai,Zhendong Chen,Zishu Wang,Jieer Ying,Yinying Lu,Zhiqiang Meng,Hongming Pan,Ping Yang,Helong Zhang,Xi Chen,Aibing Xu,Xiufeng Liu,Qiu Meng,Liqing Wu,Feng Chen +17 more
TL;DR: A novel multikinase inhibitor that showed potential benefits in a previous study and is still the standard first-line therapy for advanced hepatocellular carcinoma is presented.
Journal ArticleDOI
Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.
Qiu Li,Shukui Qin,Shanzhi Gu,Xiaoming Chen,Lizhu Lin,Zishu Wang,Aibing Xu,Xi Chen,Cuncai Zhou,Zhenggang Ren,Lin Yang,Li Xu,Yuxian Bai,Lei Chen,Jun Li,Hongming Pan,Bangwei Cao,Weijia Fang,Ping Yan,Chunlei Jin +19 more
TL;DR: Chinese patients account for more than 50% of hepatocellular carcinoma cases in the world and have special features in etiology, biological behavior, treatment strategy, and so on.